Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Advent Life Sciences LLP - 13 Feb 2026 SCHEDULE 13G/A Report for Aura Biosciences, Inc. Common Stock, par value $0.00001 per share (AURA)
- Filing manager
- Advent Life Sciences LLP
- Reporting owner
- Rajesh Parekh, Ph.D.
- Beneficially owned shares
- 2,071,857 shares
- Large-stake signal
-
Ownership
3.3%Beneficial ownership of this reported class.
Shares
2,071,857 sharesShares beneficially owned as disclosed.
Event date
13 Feb 2026Date tied to the ownership event or amendment.
Accepted by SEC
17 Feb 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 3.3%
- Symbol
- AURA
- Shares outstanding
- 62,124,648 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 17 Feb 2026, 20:48:03 UTC
- Event date
- 13 Feb 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Advent Life Sciences LLP disclosed 3.3% ownership in Aura Biosciences, Inc. Common Stock, par value $0.00001 per share (AURA) on 13 Feb 2026.
Key facts
- Advent Life Sciences LLP filed SCHEDULE 13G/A for Aura Biosciences, Inc. Common Stock, par value $0.00001 per share (AURA).
- Disclosed ownership: 3.3%.
- Date of event: 13 Feb 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 20:48.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (6)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Advent Life Sciences LLP | 3.3% | 2,023,857 | 0 | 2,023,857 | /s/Rajesh Parekh, Ph.D. | General Partner of Advent Life Sciences LLP | |
| Advent Life Sciences Fund I LP | 3.3% | 2,023,857 | 0 | 2,023,857 | /s/Rajesh Parekh, Ph.D. | General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund I LP | |
| Rajesh Parekh, Ph.D. | 3.3% | 2,071,857 | 0 | 2,023,857 | /s/Rajesh Parekh, Ph.D. | /s/Rajesh Parekh, Ph.D. | |
| Advent Life Sciences Fund III LP | 3.3% | 2,023,857 | 0 | 2,023,857 | /s/Rajesh Parekh, Ph.D. | General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund III LP | |
| ALS III Carry and Co-Invest LP | 3.3% | 2,023,857 | 0 | 2,023,857 | /s/Rajesh Parekh, Ph.D. | General Partner of Advent Life Sciences LLP acting in its capacity as Manager of ALS III Carry and Co-Invest LP | |
| Advent-Harrington Impact Fund LP | 3.3% | 2,023,857 | 0 | 2,023,857 | /s/Rajesh Parekh, Ph.D. | General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent-Harrington Impact Fund LP |
CIK / CUSIP context first